medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2013, Number 4

<< Back Next >>

Rev Esp Med Quir 2013; 18 (4)

Medical Treatment Guides of Non-Small Cell Lung Cancer at ISSSTE (Third and Last Part)

Valle SAAE, Hernández HCA, Aldaco SF, Franco GE

Language: Spanish
References: 15
Page: 328-330
PDF size: 331.14 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Ferlay J, Shin HR, Bray F, Forman D, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: http:// globocan.iarc.fr2

  2. Arrieta O, Campos-Parra AD, Zuloaga Z, Avilés A, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non–small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol 2012;(in press).

  3. Peto R, Darby S, Deo H, Silcocks P, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;5:323-329.

  4. Instituto Nacional de Estadística, Geografía e Informática, 2009. Disponible en: www.inegi.org.mx

  5. IARC-OMS. World Cancer Report 2008. Lyon: International Agency for Research on Cancer, 2008.

  6. Hoffmann D, Djordjevic MV, Hoffmann I. The changing cigarette. Prev Med 1997;26:427-434.

  7. Beelen R, Hoek G, van den Brandt PA, Goldbohm RA, et al. Long-term exposure to traffic-related air pollution and lung cancer risk. Epidemiology 2008;19:702-710.

  8. Ettinger DS, Akerley W, Bepler G, Blum MG, et al. Non-Small-Cell Lung Cancer. J Natl Compr Canc Netw 2010;8:740-801.

  9. Peters S, et al. Metastasis non-small-cell lung cancer (NSCLC): ESMO Clinical Practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2012;23(Suppl 7):vii 56-64.

  10. Gandara DR. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer 2009;10:392-394.

  11. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3, 2012.

  12. Gridellia C, de Marinisb F, et al. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011;71:249-257.

  13. Fukuoca M, Wu Y, et al. Biomarker analyses from a phase III, Randomized, open-label, first-line study of gefitinib vs carboplatino/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS) J Clin Oncol 2009;27(15s):8006.

  14. Maemondo M, Inoue A. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. NEJM 2010;326:24.

  15. Kobayashi S, Titus J. EGFR mutation and resistance of non-small-cell lung Cancer to Gefitinib. NEJM 2005;352:24.




2020     |     www.medigraphic.com